10X Genomics (TXG)
NASDAQ:TXG
Want to see TXG full AI Analyst Report?
TXG Stock Chart & Stats
$26.08
-$0.12(-0.77%)
At close: 4:00 PM EST
$26.08
-$0.12(-0.77%)
Day’s Range― - ―
52-Week Range$10.17 - $35.65
Previous CloseN/A
Volume385.49K
Average Volume (3M)3.03M
Market Cap
$3.66B
Enterprise Value$3.18B
Total Cash (Recent Filing)$539.85M
Total Debt (Recent Filing)$81.39M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Aug 06, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding116,877,320
10 Day Avg. Volume3,205,565
30 Day Avg. Volume3,029,975
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.56
Price to Sales (P/S)3.17
P/FCF Ratio15.64
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue4.99
Enterprise Value/Gross Profit7.16
Enterprise Value/Ebitda39.13
Forecast
1Y Price Target
$24.50Price Target Upside-6.06% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$613.23M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Revenue GrowthSustained consumables growth highlights a sticky, usage-based revenue stream: once labs adopt instruments they repeatedly buy reagents and chips. Durable consumables demand supports predictable recurring revenue, higher lifetime customer value, and margin resilience even if instrument sales are lumpy.
Improved Cash Generation And LiquidityPositive trailing cash flows and growing cash balances give the company financial flexibility to fund R&D, scale Atara production, and ride out instrument cyclicality. A stronger cash position and low leverage reduce refinancing risk and support strategic investments over the coming 2–6 months.
New Platform (Atara) Expands TAM And RoadmapAtara provides a structurally larger addressable market via high-throughput spatial whole-transcriptome workflows and an upgradeable roadmap (automation, multiomics, cloud). If production scales, it can increase instrument placements and drive durable consumables pull-through across translational and AI-driven biology use cases.
Bears Say
Sharp TTM Revenue DeclineA large multi-quarter revenue decline weakens operating leverage and raises sustainability concerns: fixed costs and R&D capacity can outpace sales recovery, making margin gains fragile and dependent on restoring volume growth or converting Atara orders into repeat consumables consumption.
Limited Atara Production Capacity In 2026Constrained Atara supply delays material revenue and consumables upside, slowing the platform's ability to scale TAM and demonstrate repeatable pull-through. Production bottlenecks elevate execution risk and push meaningful commercial benefits beyond the 2–6 month horizon.
Instrument Revenue Weakness And Customer Timing ShiftsFalling instrument placements reduce the expanding installed base that underpins future consumables demand. Customer delays and platform migration dynamics can suppress longer-term revenue growth and make consumables expansion dependent on a successful, timely instrument recovery.
10x Genomics News
TXG FAQ
What was 10X Genomics’s price range in the past 12 months?
10X Genomics lowest stock price was $10.17 and its highest was $35.65 in the past 12 months.
What is 10X Genomics’s market cap?
10X Genomics’s market cap is $3.66B.
When is 10X Genomics’s upcoming earnings report date?
10X Genomics’s upcoming earnings report date is Aug 06, 2026 which is in 52 days.
How were 10X Genomics’s earnings last quarter?
10X Genomics released its earnings results on May 07, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.275 by $0.175.
Is 10X Genomics overvalued?
According to Wall Street analysts 10X Genomics’s price is currently Overvalued.
Does 10X Genomics pay dividends?
10X Genomics does not currently pay dividends.
What is 10X Genomics’s EPS estimate?
10X Genomics’s EPS estimate is -0.23.
How many shares outstanding does 10X Genomics have?
10X Genomics has 116,877,320 shares outstanding.
What happened to 10X Genomics’s price movement after its last earnings report?
10X Genomics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.275. Following the earnings report the stock price went down -3.657%.
Which hedge fund is a major shareholder of 10X Genomics?
Currently, no hedge funds are holding shares in TXG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
10x Genomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.50 (-6.06% Downside)
$24.50 (-6.06% Downside)
Blogger Sentiment
Neutral
TXG Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
172.58%
12-Months-Change
Fundamentals
Return on Equity
-2.86%
Trailing 12-Months
Asset Growth
12.44%
Trailing 12-Months
Company Description
10X Genomics
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
TXG Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized a major product milestone (Atara) with strong consumables momentum, margin improvement, expense discipline, and a strengthened cash position, balanced against notable near-term headwinds in instrument revenue, limited initial Atara production capacity, and modest full-year growth guidance. Management framed the instrument declines as temporary and incorporated anticipated customer timing shifts into guidance, while positioning Atara and existing platforms to drive longer-term TAM expansion, AI-driven demand, and translational adoption.View all TXG earnings summariesTXG Revenue Breakdown
60.32% Americas
22.99% EMEA
8.45% Asia-Pacific excluding China
8.24% China
TXG Stock 12 Month Forecast
Average Price Target
$24.50
▼(-6.06% Downside)
Technical Analysis
Omnicell
―
Schrodinger
―
GeneDx Holdings
―
SOPHiA GENETICS
―
Hinge Health, Inc. Class A
―
Ownership Overview
2.51% Insiders
25.89% Mutual Funds
33.22% Other Institutional Investors
10.76% Public Companies and
Individual Investors